Sir, Neuropsychiatric (NP) involvement is a prevalent and often severe feature of systemic lupus erythematosus (SLE). Diverse factors are involved in its aetiopathogenesis and treating this condition is often quite challenging. However, clinical trials of biologic therapies in patients with SLE exclude those with severe NP manifestations. The place for the use of biologic approaches is thus even more problematic than it is for other aspects of SLE.
We performed a literature search in Medline, in order to review the evidence for the use of biologic therapies in the treatment of NPSLE, in the last five years. We selected nine studies with rituximab and one with belimumab.
Belimumab is currently the only specific targeted drug approved for the treatment of SLE. In a posthoc analysis of the system (CNS) involvement at baseline. The most common manifestation was headache (24 patients), which showed a very good response to belimumab. The improvement rates reported were 20%, 100% and 69.2% with placebo and belimumab 1 and 10 mg/kg, respectively. In addition, 21 patients had NP involvement with a BILAG score of A or B at baseline. Among those, improvement rates were, paradoxically, 83.3%, 75.0% and 42.9% for placebo (total n ¼ 6), belimumab 1 mg/kg (total n ¼ 8) and 10 mg/kg (total n ¼ 7), respectively. Caution is needed, however, in the interpretation of these results, as these trials were not designed or powered to demonstrate the efficacy of belimumab in individual organ domains, the sample size was very small, and information about the specific NPSLE features treated was not provided. Rituximab has been widely used in the treatment of SLE, even though its two major clinical trials in SLE failed to meet their primary endpoints. In respect to NPSLE, we found five retrospective observational studies, one open clinical trial, two case reports and one systematic review of case reports and case series assessing the efficacy of rituximab (Table 1) . Most studies report the use of this B-cell-depleting drug in refractory cases of NPSLE; the only exception is an open trial conducted in patients with recent-onset myelopathy, using rituximab as the first-line therapy. 2 Overall, these results are very encouraging, showing high response rates. The worst results are seen in patients with demyelinating syndrome (most cases reported neuromyelitis optica) and in patients with mood disorder, although in this case it is difficult to be sure that the mood disorder (often depression) is a true NPSLE feature and not a comorbidity.
With such a diversity of factors contributing to the aetiopathogenesis of NPSLE manifestations, it may seem overly optimistic to find a single effective targeted therapy. However, the encouraging results reported with the use of rituximab may prove otherwise. A formal randomized clinical trial of rituximab in NPSLE patients would be important to demonstrate compelling evidence of its efficacy.
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